ELECTRONIC INFORMED CONSENT MODEL DEVELOPMENT FOR IMPLEMENTATION IN CLINICAL TRIALS IN UKRAINE

Authors

  • Dobrova Vy Department of Clinical Pharmacology and Clinical Pharmacy, National University of Pharmacy, Kharkiv, Ukraine. http://orcid.org/0000-0002-5950-3513
  • ZUPANETS KО Department of Clinical Pharmacology and Clinical Pharmacy, National University of Pharmacy, Kharkiv, Ukraine.
  • Kolodyezna Ty Department of Clinical Pharmacology and Clinical Pharmacy, National University of Pharmacy, Kharkiv, Ukraine. http://orcid.org/0000-0002-4227-1787
  • Timchenko yv Department of Clinical Pharmacology and Clinical Pharmacy, National University of Pharmacy, Kharkiv, Ukraine.

DOI:

https://doi.org/10.22159/ajpcr.2017.v10i12.21044

Keywords:

Clinical trials, Electronic informed consent, Clinical trial quality management, Risk management

Abstract

Objectives: The process of signing the informed consent (IC) is one of the essential procedures during organizing and conducting the clinical trial (CT) of any new drug. During this procedure, the volunteers should read the IC form that is often difficult to understand. Analysis of literature showed lack of experience in use of electronic systems in the IC signing in Ukraine. Abroad such systems are quite new. Thus, the aim of this work is the rationale for the introduction of electronic IC to CT drugs in Ukraine and the development of its general model.

Methods: Experience in the use of electronic systems in IC signing analysis was carried out using methods of system analysis, synthesis, abstraction, and generalization.

Results: Thus, during the signing process of paper forms risks and errors may arise such as loss of paper copies and signing of an incorrect version of the document by the volunteer. With the use of electronic forms, it is possible to prevent three categories of risks in preparation and signing, such as risks in the development, use, and auditing of IC forms. The opportunities of the electronic IC system to protect trial subjects in its use during organizing and conducting of CT were showed.

Conclusions: The study showed that such systems are effective. Therefore, it seems appropriate to introduce electronic IC in CT of new drugs in Ukraine. We have formulated requirements to the system and determined its structure for optimal use.

Downloads

Download data is not yet available.

Author Biographies

Dobrova Vy, Department of Clinical Pharmacology and Clinical Pharmacy, National University of Pharmacy, Kharkiv, Ukraine.

Doctor of Pharmacy, professor, Department of Clinical Pharmacology and Clinical Pharmacy

ZUPANETS KО, Department of Clinical Pharmacology and Clinical Pharmacy, National University of Pharmacy, Kharkiv, Ukraine.

Doctor of Pharmacy, ass. professor, Department of Clinical Pharmacology and Clinical Pharmacy

Kolodyezna Ty, Department of Clinical Pharmacology and Clinical Pharmacy, National University of Pharmacy, Kharkiv, Ukraine.

PhD student of Department of Clinical Pharmacology and Clinical Pharmacy

Timchenko yv, Department of Clinical Pharmacology and Clinical Pharmacy, National University of Pharmacy, Kharkiv, Ukraine.

PhD in Medicine, assistant at Department of Clinical Pharmacology and Clinical Pharmacy

References

International Conference оn Harmonisation оf Technical Requirements for Registration оf Pharmaceuticals for Human Use. Guideline for Good Clinical Practice. ICH Harmonised Guideline Integrated Addendum to ICH E6 (R1). In: Guideline for Good Clinical Practice E6(R2); 2015. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R2__Addendum_Step2.pdf.

Zupanets KO, Dobrova VY, Kolodeznaya TY, Ratushnaya KL. The analysis of compliance with bioethical norms of signing the informed consent in organizing trials of drugs. J Chem Pharm Res 2015;7(11):756-62.

Zupanets KO, Dobrova VY, Kolodeznaya TY. Study of the trial subjects protection aspects in Phase I clinical trials and bioequivalence studies. Zaporozhye Med J 2016;2(95):93-7.

Litwin J Engagement Shift: Informed Consent in the Digital Era. Applied Clinical Trials Available from: http://www.appliedclinicaltrialsonline.com/engagement-shift-informed-consent-digital-era? pageID=4.

Use of Electronic Informed Consent: FDA Guidance. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm436811.pdf.

Onapproval of Clinical trials and Expertise of Clinical Trials and Model Regulations of the Ethics Committee: Order of Ministry of Health of Ukraine №. 690 From 23.09.2009 (A Sam ended by №. 523 From 12.07.2012, № 304 від 06.05.2014, № 966 From 18.12.2014) Available from: http://www.zakon.rada.gov.ua/cgi–bin/laws/main. cgi?nreg=z1010–09. 7. Pei LL, Umar II. The application of communication technology in hospital and community pharmacies: A brief review. Int J Pharm Pharm Sci 2015;7(3):1-5.

Umashankar V, Gurunathan S. Drug discovery: An appraisal. Int J Pharm Pharm Sci 2015;7(4):59-66.

The Essential Guide to Electronic Informed Consent. Available from: http://www.resources.crfhealth.com/ebooks/the-essential-guide-to-electronic-informed-consent-2.

Published

01-12-2017

How to Cite

Vy, D., KО Z., K. Ty, and T. yv. “ELECTRONIC INFORMED CONSENT MODEL DEVELOPMENT FOR IMPLEMENTATION IN CLINICAL TRIALS IN UKRAINE”. Asian Journal of Pharmaceutical and Clinical Research, vol. 10, no. 12, Dec. 2017, pp. 238-41, doi:10.22159/ajpcr.2017.v10i12.21044.

Issue

Section

Original Article(s)